Cellebrite DI (NASDAQ:CLBT - Get Free Report)'s stock had its "buy" rating restated by Needham & Company LLC in a note issued to investors on Wednesday,Benzinga reports. They currently have a $28.00 target price on the stock. Needham & Company LLC's price target points to a potential upside of 59.06% from the stock's current price.
Other analysts have also recently issued research reports about the company. Lake Street Capital boosted their target price on Cellebrite DI from $17.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, February 14th. JPMorgan Chase & Co. lifted their target price on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an "overweight" rating in a report on Tuesday, February 11th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Cellebrite DI currently has an average rating of "Buy" and an average price target of $23.43.
Get Our Latest Stock Report on CLBT
Cellebrite DI Trading Down 0.6 %
Shares of NASDAQ CLBT traded down $0.11 during trading on Wednesday, reaching $17.60. The company had a trading volume of 628,746 shares, compared to its average volume of 1,394,670. Cellebrite DI has a twelve month low of $10.25 and a twelve month high of $26.30. The stock has a 50-day moving average price of $20.41 and a two-hundred day moving average price of $19.97. The stock has a market capitalization of $4.22 billion, a PE ratio of -12.75, a price-to-earnings-growth ratio of 4.27 and a beta of 1.44.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. On average, sell-side analysts predict that Cellebrite DI will post 0.3 EPS for the current year.
Institutional Investors Weigh In On Cellebrite DI
A number of hedge funds have recently bought and sold shares of the business. Axon Enterprise Inc. acquired a new stake in shares of Cellebrite DI during the fourth quarter worth approximately $198,270,000. FMR LLC increased its position in shares of Cellebrite DI by 89.1% in the 4th quarter. FMR LLC now owns 10,621,344 shares of the company's stock worth $233,988,000 after purchasing an additional 5,004,587 shares during the last quarter. True Wind Capital Management L.P. raised its stake in shares of Cellebrite DI by 18.2% in the 4th quarter. True Wind Capital Management L.P. now owns 13,861,007 shares of the company's stock valued at $305,358,000 after purchasing an additional 2,130,386 shares in the last quarter. Invesco Ltd. bought a new position in shares of Cellebrite DI during the fourth quarter worth about $32,700,000. Finally, Principal Financial Group Inc. bought a new position in Cellebrite DI during the 3rd quarter worth approximately $23,402,000. Institutional investors and hedge funds own 45.88% of the company's stock.
About Cellebrite DI
(
Get Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Featured Articles
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
